Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. We are focused on expanding treatment to as many patients who could benefit by developing allogeneic T-cell immunotherapies designed to provide improved survival, reduced rates of relapse and fewer toxicities. Orca Bio’s lead investigational allogeneic T-cell immunotherapy, Orca-T, is being evaluated in a pivotal Phase 3 trial called Precision-T.